Furthermore, the TFAM expression levels in imatinib-sensitive tumor samples (n = 8) were lower than in samples from untreated patients (n = 20), while we did not find a statistically significant difference between untreated and imatinib-resistant (n = 11) cases (Figure 2g). This evidence concerns the gene TFAM and neoplasm.